This study will evaluate the safety and effectiveness of a new intravenous (IV) medication (LT3001) for adult patients who have had a stroke. This new medication is designed to restore blood flow to the area of the brain affected, and reduce inflammation in the brain. Patients who agree to be in this study will receive 6 doses of the IV study drug while in the hospital. Patients will have extra labs drawn, head imaging studies and will be followed by the study team for 90 days after their hospital admission.

The purpose of this project is to create and distribute a survey with the intent to collect data about the amount and quality of training critical care physicians receive regarding brain death (i.e., death by neurologic criteria). We are doing because teaching physicians about brain death is not standardized and the subject is complex.

To Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

The purpose of the NC Registry for Brain Health is to establish a mailing list of people who are interested in learning about ongoing research studies in North Carolina that are designed to improve brain health and prevent conditions such as Alzheimer's disease (AD). Anyone interested in learning more about this ongoing research or to get involved in these types of studies, now or in the future, may join the NC Registry for Brain Health. Joining is easy and free! You must be 18 years of age or older to register. People with and without memory disorders are welcome.

The purpose of this study is to create a biorepository of blood samples form patients with myasthenia gravis that may be used with collaborators in the development of new therapeutics for myasthenia gravis (MG).

we want to learn more about seizure activity while a patient with epilepsy is not seizing or is at "rest" using data from resting state intracranial EEG (rs-iEEG) and resting state functional MRI (rs-fMRI).

This study compares two dose strengths of a new epilepsy medicine to placebo for treatment of refractory focal onset epilepsy as measured by the change in 28-day average seizure frequency.